Show/hide main menu

News

News Highlights

King's College London spin-out nominated for two awards

Posted on 19/06/2017

cellsGammaDelta Therapeutics nominated for spin-out of the year and deal of the year

Over the last few weeks a 70-strong panel of the UK’s leading Investors, Investment Banks, Global Advisory firms, Key Opinion Leaders and Non-Executive Directors have been deliberating over the final shortlist for the 2017 Biotech and Money Awards Ceremony celebrating the UK’s Life Sciences sector and its funding, finance and investment successes over the last 12 months.

Last week, it was announced that Gammadelta Therapeutics, a King’s College London spin-out, had been shortlisted in 2 of the 11 categories at this year’s ceremony on the 14th September:

  • UK Life Science Spin-Out of the Year (in partnership with King’s College London and the Francis Crick Institute)
  • UK Life Science Deal of the Year (with Takeda)

These nominations come just a month after an investment deal worth up to $100 million with Takeda was publicly announced that will able enable the development of potentially transformative treatments for cancer and immune related disease.

Founded in 2016, GammaDelta Therapeutics Ltd, is a breakthrough Immunotherapy company incubated by the UK life science investor Abingworth. Supported by, King’s College London, the Francis Crick Institute and Cancer Research Technology the company has been founded on pioneering research into gamma delta (γδ) T cells led by Professor Adrian Hayday and Dr Oliver Nussbaumer at King’s College London and the Francis Crick Institute.

Gamma delta T cells are a unique and conserved population of lymphocytes that contribute to many types of immune responses and immunopathologies. The new company is focused on exploiting their properties to develop improved immunotherapies for cancer and other serious immune related diseases.

“King’s is delighted that GammaDelta Therapeutics has been nominated for spin-out of the year and deal of the year by some of the most prominent investors and decision makers in the UK Life Sciences and Biotechnology sector. The company has its roots in research undertaken at King’s and the Crick by Professor Hayday and Dr Nussbaumer; their continued success reflects the commitment of Adrian, Oliver and others to not only world class science, but to improving the lives of patients.”  Chris Mottershead, Senior Vice President Quality, Strategy & Innovation, King’s College London.

Discover more about GammaDelta Therpeutics: https://gammadeltatx.com/

View the full list of categories and nominees and take part in the public vote: http://www.biotechandmoney.com/gala-dinner-awards

Rss Feed Atom Feed

News Highlights:

News Highlights...RSS FeedAtom Feed

Drop in violence associated with smoke-free policy at psychiatric hospital

Description
New King's College London research reveals a 39 per cent drop in physical assaults - both between patients and towards staff - following the introduction of a smoke-free policy at the South London and Maudsley NHS Foundation Trust (SLaM).

Epigenetic changes at birth could explain later behaviour problems

Description
Epigenetic changes present at birth - in genes related to addiction and aggression - could be linked to conduct problems in children, according to a new study by King's College London and the University of Bristol.

Fake online profiles easier to fish out with new software tool

Description
People who use fake profiles online could be more easily identified, thanks to a new tool developed by computer scientists from King's and the University of Edinburgh who trained computer models to spot social media users who make up information about themselves.

Share this story:

 

Follow Us

@kingscollegelon

Live Twitter feed...

@kingscollegelon
Join the conversation
Sitemap Site help Terms and conditions Privacy policy Accessibility Modern slavery statement Contact us

© 2017 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454